亨廷頓�。℉D）是一種罕見的致命的神經退化性疾病，亞洲每十萬人中大約有0.4人患病，平均發病年齡為40歲。舞蹈�。�無意識的、隨機和突然的扭動和/或轉動）是這種疾病最為顯著的表現之一，發生在大約90%的病人當中。

About chorea associated with Huntington's disease (HD)

Huntington's disease is a rare but fatal neurodegenerative disease, affecting about 0.4 per 100,000 people in Asia, with an average age of 40 years. Chorea (involuntary, random and sudden twists and/or turns) is one of the most prominent signs of the disease and occurs in approximately 90% of patients.

遲發性運動障礙（TD）是一種使人衰弱的運動紊亂，以舌頭、嘴唇、臉、軀體和四肢部位的重復且不可控的運動為特征。TD在長期接受抗精神病藥治療的中國的精神分裂癥患者當中的患病率為33.7%，可能是由某些用于治療精神健康狀況的藥物引起的，這意味著使用這些藥物的精神分裂癥患者中有三分之一可能患有TD。

About Tardive Dyskinesia (TD) in adults

Tardive Dyskinesia is a debilitating movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, body, and limbs. TD has a prevalence of 33.7% among Chinese schizophrenia patients receiving long-term antipsychotic treatment and may be caused by certain drugs used to treat mental health conditions, meaning that one-third of schizophrenics using these drugs may have TD.

安泰坦®是梯瓦創新研發的原研藥，于2017年4月獲得美國FDA批準，是FDA首次批準的氘代產品，也是針對與亨廷頓病有關的舞蹈病的歷史上第二個藥物；在美國的獲批適應癥包括與亨廷頓�。℉D）有關的舞蹈病以及成人遲發性運動障礙（TD）。其中TD適應癥被批準為突破性治療。FDA對安泰坦®的批準代表了HD患者的一個重要的新治療選擇。

About Austedo®

Austedo®, a drug innovatively developed by Teva, was approved by FDA in April 2017. It is the first FDA approved deuterium product and the second drug in the history related to chorea associated with Huntington's disease (HD). Approved indications in the United States include Chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults. The TD indication was approved as a breakthrough therapy. FDA approval of Austedo® represents an important new treatment option for HD patients.